PCSA Stock Overview
A clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Processa Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.87 |
| 52 Week High | US$9.28 |
| 52 Week Low | US$0.81 |
| Beta | 0.58 |
| 1 Month Change | 1.27% |
| 3 Month Change | -34.51% |
| 1 Year Change | -89.60% |
| 3 Year Change | -99.15% |
| 5 Year Change | -99.76% |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully
Dec 12
Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?
Oct 20Processa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73
Aug 12We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully
Jul 07We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate
Jan 20Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans
Aug 26Processa Pharmaceuticals (PCSA) Presents At LD Micro Invitations XI Virtual Conference - Slideshow
Jun 15What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?
Mar 15Processa Pharmaceuticals: Multiple Shots On Goal With Total TAM Of $8B - Worth A Look
Jan 29How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?
Jan 20
Shareholder Returns
| PCSA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -13.8% | 0.6% | -0.4% |
| 1Y | -89.6% | 10.0% | 24.8% |
Return vs Industry: PCSA underperformed the US Pharmaceuticals industry which returned 9.7% over the past year.
Return vs Market: PCSA underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| PCSA volatility | |
|---|---|
| PCSA Average Weekly Movement | 13.1% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PCSA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PCSA's weekly volatility has decreased from 28% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 13 | George Ng | www.processapharmaceuticals.com |
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company’s pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.
Processa Pharmaceuticals, Inc. Fundamentals Summary
| PCSA fundamental statistics | |
|---|---|
| Market cap | US$2.85m |
| Earnings (TTM) | -US$11.53m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs PCSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PCSA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$11.53m |
| Earnings | -US$11.53m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.53 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PCSA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 08:41 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Processa Pharmaceuticals, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robin Garner Kalley | Craig-Hallum Capital Group LLC |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| François Brisebois | Oppenheimer & Co. Inc. |